sales@tolobio.com

吐露港生物科技有限公司

   

    吐露港公司致力于为体外诊断行业提供创新型解决方案!

    公司首次发现CRISPR-Cas12蛋白具备高效的“反式切割活性”,并基于该酶的独特优势研发了“福尔摩斯/HOLMES”核酸快速检测平台技术(one-HOur Low-cost Multipurpose highly Efficient System)。相比于传统的分子诊断技术,基于CRISPR的HOLMES技术具备高灵敏、高特异、快速便捷等优势。此类技术也因此被美国《Science》杂志誉为“下一代分子诊断技术”,在病原菌检测、遗传疾病筛查、精准医疗等众多领域有很大的应用潜力。


    公司拥有Cas12核酸检测的方法学专利(中国发明专利,专利号:ZL201710573752.0),并通过与美国Sherlock Biosciences公司以“交叉授权”方式获得了Cas13诊断技术在大中华区(包括香港、澳门和台湾地区)的独家授权。

    公司目前正在积极推动SHERLOCK和HOLMES两大平台技术在分子POCT、临床感染检测、肿瘤早筛和伴随诊断、家庭检测等方面的应用,并诚愿携手体外诊断同行,共推CRISPR诊断产业的快速发展。

 





About Tolo Biotechnology



    Tolo Biotech aims to provide cutting-edge solutions for in vitro diagnostics (IVD).


    The company recently developed the HOLMES platform (one-HOur Low-cost Multipurpose highly Efficient System) with the employment of the CRISPR-Cas12 trans-cleavage activities, which were characterized by Tolo. In comparison with traditional IVD technologies, the CRISPR-based HOLMES technology shows great advantages in rapidness, convenience, high sensitivity and high specificity. As a result, CRISPR-based diagnostic technologies have been recognized as the ‘next-generation diagnostic’ technologies with great potentials in many application scenarios such as the pathogen detection, genetic screening and precision medicine.


    The company owns the Cas12 patents in diagnostics and exclusively obtained the Cas13 diagnostic techniques in Greater China through cross-licensing collaboration with Sherlock Biosciences.


    The company is willing to collaborate with IVD fellows to promote the application of CRISPR-Dx technologies in POCT, clinical pathogen diagnostics, cancer screening, food safety, etc.






引用文献(References):

1. Li et al., CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA. Cell Research 2018, 28: 491–493.

2. Li et al., CRISPR-Cas12a-assisted nucleic acid detection. Cell Discovery 2018, 4: 20.

3. Li et al., CRISPR/Cas Systems towards Next-Generation Biosensing. Trends in Biotechnology 2018, 37(7): 730-743.

4. Li et al., HOLMESv2: a CRISPR-Cas12b-assisted platform for nucleic acid detection and DNA methylation quantitation. ACS Synthetic Biology 2019, 8(10):2228-2237.

5. Huang et al., A CRISPR-Cas12a-based specific enhancer for more sensitive detection of SARS-CoV-2 infection. EBioMedicine 2020, 61: 103036.

6. Leung et al., CRISPR-Cas12-based nucleic acids detection systems. Methods 2021, S1046-2023(21)00063-3.  

7. Sam et al., TB-QUICK: CRISPR-Cas12b-assisted rapid and sensitive detection of Mycobacterium tuberculosis. J Infect. 2021, S0163-4453(21)00219-X.

8. 一种Cas蛋白的用途及靶标核酸分子的检测方法和试剂盒 ZL201710573752.0

9. 基于CRISPR效应系统的诊断(CN110506128

10. 用于病毒检测的基于CRISPR效应系统的诊断(CN111108220


联系我们

总部

  • 上海市徐汇区桂平路333号6号楼402室
  • 400-032-6070
  • SUPPORT@TOLOBIO.COM

上海

上海市徐汇区桂平路333号(聚科生物园区)6号楼402室

400-032-6070

SALES@TOLOBIO.COM

安徽

安徽省滁州市世纪大道801号(昭阳工业园)8号楼201室

0550-3022115

SALES@TOLOBIO.COM